The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

ABL1  -  ABL proto-oncogene 1, non-receptor...

Homo sapiens

Synonyms: ABL, Abelson murine leukemia viral oncogene homolog 1, Abelson tyrosine-protein kinase 1, JTK7, Proto-oncogene c-Abl, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ABL1


Psychiatry related information on ABL1


High impact information on ABL1


Chemical compound and disease context of ABL1


Biological context of ABL1


Anatomical context of ABL1


Associations of ABL1 with chemical compounds


Physical interactions of ABL1

  • CONCLUSIONS: RIN1 is a directly binding ABL tyrosine kinase activator in cells as well as in a defined-component assay [23].
  • Paxillin coprecipitated with p210BCR/ABL and multiple other cellular proteins in myeloid cell lines, suggesting the formation of multimeric complexes [24].
  • After BCR/ABL transformation, both the CRKL- and CRK-SH2 domains bound to a new complex of proteins of approximate molecular weight 105-120 kDa [25].
  • Molecular cytogenetic analysis confirmed that formation of an ETV6/ABL1 fusion in these patients required at least three chromosomal breaks and showed that each of these translocations is the result of a complex chromosomal rearrangement [26].
  • Ku70 coprecipitated with c-ABL and p21 after irradiation [27].

Enzymatic interactions of ABL1


Regulatory relationships of ABL1

  • The shift in ABL transcriptional control to the BCR promoter may play a role in cellular transformation mediated by this rearrangement [30].
  • BCR/ABL-induced VEGF expression may contribute to the pathogenesis and increased angiogenesis in CML [12].
  • BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway [31].
  • These data argue that BCR-ABL is directly responsible for the enhanced response to SCF reported in CML progenitor cells [32].
  • BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5 [33].

Other interactions of ABL1

  • Loss of p53 impedes the antileukemic response to BCR-ABL inhibition [34].
  • Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2 [35].
  • Detailed FISH analysis identified a cryptic t(9;12) translocation, and molecular studies confirmed the presence of the ETV6-ABL fusion transcript [36].
  • Meg-01 cells express a p185 BCR/ABL oncogene, which may be responsible for the constitutive activation of STAT5 [37].
  • Among them, PDGFRbeta, ABL, JAK2, and TRKC are tyrosine kinases (TK) [38].

Analytical, diagnostic and therapeutic context of ABL1


  1. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Graux, C., Cools, J., Melotte, C., Quentmeier, H., Ferrando, A., Levine, R., Vermeesch, J.R., Stul, M., Dutta, B., Boeckx, N., Bosly, A., Heimann, P., Uyttebroeck, A., Mentens, N., Somers, R., MacLeod, R.A., Drexler, H.G., Look, A.T., Gilliland, D.G., Michaux, L., Vandenberghe, P., Wlodarska, I., Marynen, P., Hagemeijer, A. Nat. Genet. (2004) [Pubmed]
  2. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R.A., Li, S. Nat. Genet. (2004) [Pubmed]
  3. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Issa, J.P., Kantarjian, H., Mohan, A., O'Brien, S., Cortes, J., Pierce, S., Talpaz, M. Blood (1999) [Pubmed]
  4. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Asimakopoulos, F.A., Shteper, P.J., Krichevsky, S., Fibach, E., Polliack, A., Rachmilewitz, E., Ben-Neriah, Y., Ben-Yehuda, D. Blood (1999) [Pubmed]
  5. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Giehl, M., Fabarius, A., Frank, O., Erben, P., Zheng, C., Hafner, M., Hochhaus, A., Hehlmann, R., Seifarth, W. Leukemia (2007) [Pubmed]
  6. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Topaly, J., Fruehauf, S., Ho, A.D., Zeller, W.J. Br. J. Cancer (2002) [Pubmed]
  7. A case of abetalipoproteinaemia in a Polish family. Kaciński, M., Kaczmarski, F., Miezyński, W., Grzenda-Adamek, Z., Miszczuk-Jamska, B., Stopyrowa, J., Sznajd, J. Eur. J. Pediatr. (1991) [Pubmed]
  8. The BCR-ABL story: bench to bedside and back. Wong, S., Witte, O.N. Annu. Rev. Immunol. (2004) [Pubmed]
  9. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Barbouti, A., Ahlgren, T., Johansson, B., Höglund, M., Lassen, C., Turesson, I., Mitelman, F., Fioretos, T. Br. J. Haematol. (2003) [Pubmed]
  10. Imatinib resistance: obstacles and opportunities. Litzow, M.R. Arch. Pathol. Lab. Med. (2006) [Pubmed]
  11. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Muller, A.J., Pendergast, A.M., Havlik, M.H., Puil, L., Pawson, T., Witte, O.N. Mol. Cell. Biol. (1992) [Pubmed]
  12. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Mayerhofer, M., Valent, P., Sperr, W.R., Griffin, J.D., Sillaber, C. Blood (2002) [Pubmed]
  13. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Błasiak, J., Gloc, E., Młynarski, W., Drzewoski, J., Skórski, T. Leuk. Res. (2002) [Pubmed]
  14. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. Klein, F., Feldhahn, N., Harder, L., Wang, H., Wartenberg, M., Hofmann, W.K., Wernet, P., Siebert, R., Müschen, M. J. Exp. Med. (2004) [Pubmed]
  15. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). De Keersmaecker, K., Graux, C., Odero, M.D., Mentens, N., Somers, R., Maertens, J., Wlodarska, I., Vandenberghe, P., Hagemeijer, A., Marynen, P., Cools, J. Blood (2005) [Pubmed]
  16. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Huettner, C.S., Zhang, P., Van Etten, R.A., Tenen, D.G. Nat. Genet. (2000) [Pubmed]
  17. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. La Starza, R., Trubia, M., Testoni, N., Ottaviani, E., Belloni, E., Crescenzi, B., Martelli, M., Flandrin, G., Pelicci, P.G., Mecucci, C. Haematologica (2002) [Pubmed]
  18. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. Matsuguchi, T., Inhorn, R.C., Carlesso, N., Xu, G., Druker, B., Griffin, J.D. EMBO J. (1995) [Pubmed]
  19. The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation. Kadlec, L., Pendergast, A.M. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  20. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. Okuda, K., D'Andrea, A., Etten, R.A., Griffin, J.D. J. Clin. Invest. (1997) [Pubmed]
  21. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Pendergast, A.M., Muller, A.J., Havlik, M.H., Clark, R., McCormick, F., Witte, O.N. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  22. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Stover, E.H., Chen, J., Lee, B.H., Cools, J., McDowell, E., Adelsperger, J., Cullen, D., Coburn, A., Moore, S.A., Okabe, R., Fabbro, D., Manley, P.W., Griffin, J.D., Gilliland, D.G. Blood (2005) [Pubmed]
  23. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Hu, H., Bliss, J.M., Wang, Y., Colicelli, J. Curr. Biol. (2005) [Pubmed]
  24. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. Salgia, R., Li, J.L., Lo, S.H., Brunkhorst, B., Kansas, G.S., Sobhany, E.S., Sun, Y., Pisick, E., Hallek, M., Ernst, T. J. Biol. Chem. (1995) [Pubmed]
  25. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Uemura, N., Salgia, R., Li, J.L., Pisick, E., Sattler, M., Griffin, J.D. Leukemia (1997) [Pubmed]
  26. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Van Limbergen, H., Beverloo, H.B., van Drunen, E., Janssens, A., Hählen, K., Poppe, B., Van Roy, N., Marynen, P., De Paepe, A., Slater, R., Speleman, F. Genes Chromosomes Cancer (2001) [Pubmed]
  27. Expression, localization and functional interactions of Ku70 subunit of DNA-PK in peripheral lymphocytes and Nalm-19 cells after irradiation. Kumaravel, T.S., Bharathy, K., Kudoh, S., Tanaka, K., Kamada, N. Int. J. Radiat. Biol. (1998) [Pubmed]
  28. The second ETV6 allele is not necessarily deleted in acute leukemias with a ETV6/ABL fusion. Hannemann, J.R., Healy, L.E., Ridge, S.A., Wiedemann, L.M. Genes Chromosomes Cancer (1998) [Pubmed]
  29. c-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein. Zhu, J., Shore, S.K. Mol. Cell. Biol. (1996) [Pubmed]
  30. Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. Shah, N.P., Witte, O.N., Denny, C.T. Mol. Cell. Biol. (1991) [Pubmed]
  31. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. Gesbert, F., Sellers, W.R., Signoretti, S., Loda, M., Griffin, J.D. J. Biol. Chem. (2000) [Pubmed]
  32. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Pierce, A., Spooncer, E., Ainsworth, S., Whetton, A.D. Oncogene (2002) [Pubmed]
  33. BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5. Ahmed, M., Dusanter-Fourt, I., Dugray, A., Dubrez, L., Novault, S., Bonnet, M.L., Gisselbrecht, S., Varet, B., Solary, E., Vainchenker, W., Turhan, A.G. Leuk. Lymphoma (2001) [Pubmed]
  34. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Wendel, H.G., de Stanchina, E., Cepero, E., Ray, S., Emig, M., Fridman, J.S., Veach, D.R., Bornmann, W.G., Clarkson, B., McCombie, W.R., Kogan, S.C., Hochhaus, A., Lowe, S.W. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  35. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Sánchez-García, I., Grütz, G. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  36. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. O'Brien, S.G., Vieira, S.A., Connors, S., Bown, N., Chang, J., Capdeville, R., Melo, J.V. Blood (2002) [Pubmed]
  37. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Liu, R.Y., Fan, C., Garcia, R., Jove, R., Zuckerman, K.S. Blood (1999) [Pubmed]
  38. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Iijima, Y., Ito, T., Oikawa, T., Eguchi, M., Eguchi-Ishimae, M., Kamada, N., Kishi, K., Asano, S., Sakaki, Y., Sato, Y. Blood (2000) [Pubmed]
  39. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Buño, I., Wyatt, W.A., Zinsmeister, A.R., Dietz-Band, J., Silver, R.T., Dewald, G.W. Blood (1998) [Pubmed]
  40. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Loncarevic, I.F., Römer, J., Starke, H., Heller, A., Bleck, C., Ziegler, M., Fiedler, W., Liehr, T., Clement, J.H., Claussen, U. Genes Chromosomes Cancer (2002) [Pubmed]
  41. Identification of genes differentially regulated by the P210 BCR/ABL1 fusion oncogene using cDNA microarrays. Håkansson, P., Segal, D., Lassen, C., Gullberg, U., Morse, H.C., Fioretos, T., Meltzer, P.S. Exp. Hematol. (2004) [Pubmed]
  42. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements. Pelz, A.F., Kröning, H., Franke, A., Wieacker, P., Stumm, M. Ann. Hematol. (2002) [Pubmed]
WikiGenes - Universities